Your browser doesn't support javascript.
loading
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Anna, François; Goyard, Sophie; Lalanne, Ana Ines; Nevo, Fabien; Gransagne, Marion; Souque, Philippe; Louis, Delphine; Gillon, Véronique; Turbiez, Isabelle; Bidard, François-Clément; Gobillion, Aline; Savignoni, Alexia; Guillot-Delost, Maude; Dejardin, François; Dufour, Evelyne; Petres, Stéphane; Richard-Le Goff, Odile; Choucha, Zaineb; Helynck, Olivier; Janin, Yves L; Escriou, Nicolas; Charneau, Pierre; Perez, Franck; Rose, Thierry; Lantz, Olivier.
Afiliación
  • Anna F; Theravectys, Paris, France.
  • Goyard S; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France.
  • Lalanne AI; INSERM 1221, Institut Pasteur, Paris, France.
  • Nevo F; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
  • Gransagne M; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Souque P; Theravectys, Paris, France.
  • Louis D; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France.
  • Gillon V; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France.
  • Turbiez I; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
  • Bidard FC; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Gobillion A; Direction of the Clinical Research, Institut Curie, Paris, France.
  • Savignoni A; Direction of the Clinical Research, Institut Curie, Paris, France.
  • Guillot-Delost M; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Dejardin F; Medical Oncology Department, Institut Curie, Paris, France.
  • Dufour E; UVSQ, Paris-Saclay University, Saint-Cloud, France.
  • Petres S; Biometry, Institut Curie, Paris, France.
  • Richard-Le Goff O; Biometry, Institut Curie, Paris, France.
  • Choucha Z; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Helynck O; INSERM U932, PSL University, Institut Curie, Paris, France.
  • Janin YL; Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.
  • Escriou N; Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.
  • Charneau P; Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.
  • Perez F; Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, France.
  • Rose T; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France.
  • Lantz O; Unit of Chemistry and Biocatalysis, Institut Pasteur, CNRS UMR 3523, Paris, France.
Eur J Immunol ; 51(1): 180-190, 2021 01.
Article en En | MEDLINE | ID: mdl-33259646
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: COVID-19 / Anticuerpos Antivirales Tipo de estudio: Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Eur J Immunol Año: 2021 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: COVID-19 / Anticuerpos Antivirales Tipo de estudio: Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Eur J Immunol Año: 2021 Tipo del documento: Article País de afiliación: Francia